Key facts
- Aether Bio’s last known valuation is $110.0M (Dec 2025).
- It has raised $73.9M; the latest was Later Stage VC ($15.0M) in Dec 2025.
- Notable investors include Gaingels, BoxGroup, Calm Ventures, Abstract Ventures, Tribe Capital — 28 tracked in total.
- Status: Privately Held (backing).
Leadership
- Jay ZaveriFounder & President
- ·The complete investor list — 28 names
- ·Watchlist + deal alerts for Aether Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Aether Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aether Bio
Developer of a biocatalyst engineering technology designed to repurpose enzymes to create a new compound. The company's technology utilizes machine learning combined with high-throughput robotic laboratories to engineer enzymes rapidly and allows massively parallelized experimentation, generating datasets orders of magnitude larger, enabling researchers to manufacture complex and novel medical products at a fraction cost.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2017
- Employees
- 38
- Website
- aetherbio.com/
- Ownership
- Privately Held (backing)
Aether Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aether Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aether Bio in its N-PORT filings yet. We sweep new filings monthly.